CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

April 26, 2019

Study Completion Date

June 1, 2020

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Placebo

oral tablets

DRUG

CB-839

oral tablets

DRUG

everolimus

oral tablets

Trial Locations (38)

10065

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Medical Center, The Bronx

11501

NYU Winthrop Hospital - Cancer Clinical Trials Oncology/Hematology, Mineola

11733

North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists, East Setauket

13210

SUNY Upstate Medical University, Syracuse

15063

Monongahela Valley Hospital, Monongahela

17604

Ann B. Barshinger Cancer Institute / Lancaster General Hospital, Lancaster

21201

University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore

21401

Anne Arundel Medical Center Oncology and Hematology, Annapolis

29414

Charleston Hematology Oncology Associates,PA, Charleston

30060

Northwest Georgia Oncology Centers, P.C., Marietta

30607

University Cancer & Blood Center, LLC, Athens

33705

Florida Cancer Specialists- North, St. Petersburg

33901

Florida Cancer Specialists- South, Fort Myers

37203

Sarah Cannon Research Institute - Tennessee Oncology, Nashville

37403

UT/Erlanger Oncology & Hematology, Chattanooga

40202

Norton Cancer Institute, Norton Healthcare Pavilion, Louisville

45219

University of Cincinnati Medical Center, Cincinnati

46845

Parkview Research Center, Fort Wayne

52242

University of Iowa Hospitals and Clinics, Iowa City

53705

University of Wisconsin Carbone Cancer Center, Madison

55416

Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park

59102

St. Vincent Frontier Cancer Center, Billings

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

64132

SCRI HCA Midwest, Kansas City

64804

Mercy Clinic Oncology & Hematology, Joplin

70121

Ochsner Clinical Foundation, New Orleans

72758

Highlands Oncology Group, Rogers

77030

The University of Texas MD Anderson Cancer Center, Houston

83712

St. Luke's Mountain States Tumor Institute, Boise

84106

Utah Cancer Specialists, Salt Lake City

85724

The University of Arizona Cancer Center, Tucson

89148

Comprehensive Cancer Centers of Nevada, Las Vegas

90017

Los Angeles Hematology Oncology Medical Group, Los Angeles

90095

UCLA Department of Medicine - Hematology/Oncology, Los Angeles

94305

Stanford Cancer Center, Stanford

98801

Wenatchee Valley Hospital and Clinics, Wenatchee

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY

NCT03163667 - CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) | Biotech Hunter | Biotech Hunter